GS vs MS: side-by-side analysis
Cross-read of GS (The Goldman Sachs Group Inc.) versus MS (Morgan Stanley): GS looks meaningfully overvalued at $936 versus a fair-value midpoint of $628, while MS appears in our peer table at a forward P/E of 15.2x and ROE of 16.4%. Our current rating for GS is Sell.
Where GS and MS sit on fair value
GS's composite fair-value range is $451–$787 (midpoint $628), versus a current price of $936. MS is one of GS's closest sector neighbours and shows up directly in the peer table inside our full report, with a market-cap of $304.6B, P/E of 15.2x, EV/EBITDA of , and an operating margin of 40.6%. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between GS and MS is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
GS is classified as a financial stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. MS, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 14.3× forward P/E with a PEG of 2.86 is not the same on GS as it is on MS unless they share the same growth profile, capital intensity, and moat half-life.
GS's moat assessment is 6.5/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against MS should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: GS looks meaningfully overvalued versus our fair-value midpoint. The full report's peer table compares GS and MS directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for GS is bound by the kill-scenarios list in Section 2; the equivalent for MS would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether GS or MS is the better expression of the same theme.
Bottom line — GS or MS?
Our rating for GS is Sell with a 73/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes MS. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on GS, including the explicit peer multiples versus MS and the rest of the comp set, see the canonical report at /stocks/gs/analysis. For MS's standalone report, see /stocks/ms/analysis.
Frequently asked questions
GS vs MS: which is cheaper today?
GS looks meaningfully overvalued at $936 versus a fair-value midpoint of $628 (range $451–$787). The peer table inside the full report compares GS and MS directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is GS a better buy than MS?
Our current rating for GS is Sell; we do not co-rate MS on this page — see MS's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is GS?
The Goldman Sachs Group Inc. is classified as a financial stock, which determines our deceleration curve, terminal multiple, and probability weights. MS's own archetype is in its own report.
What is GS's moat score versus MS?
GS's moat score is 6.5/10. The full moat section covers source, durability, and threat timeline; MS's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full GS report for the canonical evidence.